Cargando…

PB2251: SOMETIMES IT’S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT

Detalles Bibliográficos
Autores principales:	Catana, Alina, Mera, Geanina, Popa, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429730/ http://dx.doi.org/10.1097/01.HS9.0000975736.18321.52

Ejemplares similares

PB2569: ALAS! PORPHYRIA OR SIDEROBLASTIC ANEMIA? A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

PB1998: AZACYTIDINE AND ALLOGENOUS STEM CELL TRANSPLANTATION IN LATE-ONSET ERYTHROPOIETIC PROTOPORPHYRIA
por: Fassi, Daniel El, et al.
Publicado: (2023)

PB2562: STUDY DESIGN OF THE AURORA TRIAL: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA
por: Levy, Cynthia, et al.
Publicado: (2023)

PB2559: VARIEGATE PORPHYRIA CONFIRMED BY NGS AND TREATED WITH GIVOSIRAN - CASE PRESENTATION
por: Georgescu, Georgeta Daniela
Publicado: (2023)

PB2251: TWO POLYCYTHEMIA VERA PATIENTS WITH A DIAGNOSIS OF CONCOMITANT HEREDITARY HEMOCHROMATOSIS
por: Kiper Unal, H. D., et al.
Publicado: (2022)

Erythropoietic protoporphyria
por: Lecha, Mario, et al.
Publicado: (2009)

Microcytosis in Erythropoietic Protoporphyria
por: Graziadei, Giovanna, et al.
Publicado: (2022)

Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy
por: Yoshida, Akihiro, et al.
Publicado: (2018)

How I treat erythropoietic protoporphyria and X-linked protoporphyria
por: Leaf, Rebecca Karp, et al.
Publicado: (2023)

The role of ClpX in erythropoietic protoporphyria
por: Whitman, Jared C., et al.
Publicado: (2018)

UK experience of liver transplantation for erythropoietic protoporphyria
por: Dowman, Joanna K., et al.
Publicado: (2011)

Laparoscopic Cholecystectomy in a Patient with Erythropoietic Protoporphyria
por: Roe, Thomas, et al.
Publicado: (2010)

Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016)

Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria
por: Dickey, Amy K., et al.
Publicado: (2020)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria
por: Balwani, Manisha, et al.
Publicado: (2022)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

An Unusual Case of Erythropoietic Protoporphyria Mimicking Lipoid Proteinosis
por: Kaur, Sarabjit, et al.
Publicado: (2019)

Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria
por: Di Pierro, Elena, et al.
Publicado: (2022)

Erythropoietic protoporphyria: Delayed presentation with decompensated liver disease
por: Sarda, Radhika, et al.
Publicado: (2020)

Current trials in erythropoietic protoporphyria: are placebo controls ethical?
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2023)

Erythropoietic protoporphyria: case reports for clinical and therapeutic hints
por: Tumminelli, Cristina, et al.
Publicado: (2023)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION
por: Moura, Pedro, et al.
Publicado: (2023)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
por: Naik, Hetanshi, et al.
Publicado: (2019)

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY
por: Huang, J., et al.
Publicado: (2022)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

PB2228: WHAT IS THE UTILITY OF THE MYSEC-PM ON SECONDARY MYELOFIBROSIS RISK STRATIFICATION IN A REAL LIFE SETTING?
por: Moura, Pedro, et al.
Publicado: (2023)

Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria
por: Teramura, Takashi, et al.
Publicado: (2017)

The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria
por: Wang, Pengcheng, et al.
Publicado: (2019)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_njlgnapo9tgfqbojguthquslgm